Lok, Benjamin H <br/><br/>
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2017 
 - 523-535 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-1040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Cell Line, Tumor<br/>Cisplatin--administration & dosage<br/>Dacarbazine--administration & dosage<br/>Drug Synergism<br/>Etoposide--administration & dosage<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genomics--methods<br/>Humans<br/>Indoles--administration & dosage<br/>Mice<br/>Nuclear Proteins--genetics<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors<br/>Poly(ADP-ribose) Polymerase Inhibitors--administration & dosage<br/>Small Cell Lung Carcinoma--drug therapy<br/>Temozolomide<br/>Xenograft Model Antitumor Assays